Wellington Management Group
TGTX icon

Wellington Management Group’s TG Therapeutics TGTX Stock Holding History

Wellington Management Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.3M Buy
478,265
+418,300
+698% +$17.1M ﹤0.01% 958
2026
Q1 		$1.99M Sell
59,965
-1,542
-3% -$46K ﹤0.01% 1550
2025
Q4 		$1.83M Buy
61,507
+903
+1% +$29.5K ﹤0.01% 1615
2025
Q3 		$2.19M Sell
60,604
-1,168,995
-95% -$38.5M ﹤0.01% 1609
2025
Q2 		$44.3M Buy
1,229,599
+16,560
+1% +$617K 0.01% 719
2025
Q1 		$47.8M Buy
1,213,039
+1,149,526
+1,810% +$38.7M 0.01% 692
2024
Q4 		$1.91M Sell
63,513
-9,807
-13% -$281K ﹤0.01% 1576
2024
Q3 		$1.71M Buy
73,320
+8,249
+13% +$180K ﹤0.01% 1580
2024
Q2 		$1.16M Sell
65,071
-3,088,522
-98% -$49.3M ﹤0.01% 1639
2024
Q1 		$48M Buy
3,153,593
+13,829
+0.4% +$220K 0.01% 715
2023
Q4 		$53.6M Buy
3,139,764
+43,290
+1% +$503K 0.01% 690
2023
Q3 		$25.9M Sell
3,096,474
-63,138
-2% -$880K 0.01% 891
2023
Q2 		$78.5M Sell
3,159,612
-168,739
-5% -$4.36M 0.01% 604
2023
Q1 		$50.1M Sell
3,328,351
-105,099
-3% -$1.6M 0.01% 692
2022
Q4 		$40.6M Sell
3,433,450
-988,672
-22% -$7.18M 0.01% 736
2022
Q3 		$26.2M Buy
4,422,122
+234,678
+6% +$1.54M 0.01% 838
2022
Q2 		$17.8M Buy
4,187,444
+166,968
+4% +$1.04M ﹤0.01% 969
2022
Q1 		$38.2M Sell
4,020,476
-230,194
-5% -$2.66M 0.01% 840
2021
Q4 		$80.8M Buy
4,250,670
+2,674,941
+170% +$69.4M 0.01% 686
2021
Q3 		$52.4M Sell
1,575,729
-2,671,948
-63% -$82.7M 0.01% 804
2021
Q2 		$165M Sell
4,247,677
-69,084
-2% -$2.71M 0.03% 489
2021
Q1 		$208M Sell
4,316,761
-601,072
-12% -$28.9M 0.04% 417
2020
Q4 		$256M Buy
4,917,833
+1,610,787
+49% +$54.4M 0.05% 351
2020
Q3 		$88.5M Buy
+3,307,046
New +$76.1M 0.02% 551
2018
Q2 		– Sell
-106,021
Closed -$1.51M – 2314
2018
Q1 		$1.51M Buy
+106,021
New +$1.35M ﹤0.01% 1810

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Wellington Management Group's TGTX Position: Q2 2026 in Review

Wellington Management Group increased its TG Therapeutics (TGTX) stake by 698% in Q2 2026, buying an estimated $17.1M and bringing the position to 478,265 shares worth $26.3M. The position accounts for ﹤0.01% of the portfolio, ranked #958.

Wellington Management Group first reported a position in TGTX in Q1 2018 and has held it in 25 quarters since. The position peaked at $256M in Q4 2020. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Wellington Management Group held 478,265 shares of TG Therapeutics worth $26.3M as of Q2 2026.
  • Wellington Management Group bought 418,300 TG Therapeutics shares in Q2 2026, an estimated $17.1M.
  • TG Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #958 holding.
  • Wellington Management Group first reported a position in TG Therapeutics in Q1 2018 and has held it in 25 quarters since.
  • Wellington Management Group's TG Therapeutics position peaked at $256M in Q4 2020.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.